Superior EFS and OS in Patients with Nonmetastatic Osteosarcoma and Unfavourable Prognosis when Adjuvant Mifamurtide is Combined with High-Dose Ifosfamide By Ogkologos - August 28, 2025 268 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ISG/OS-2 and GEIS-33 studies Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Boy Shaves Head To Support Friend Going Through Cancer October 1, 2021 Fake Amazon Delivery Driver Attempts to Steal Elderly Woman’s Cancer Drugs February 19, 2020 Charity ‘looks to the future with renewed optimism’ July 21, 2021 Niraparib Maintenance Significantly Reduces the Risk of Disease Progression or Death... July 31, 2023 Load more HOT NEWS Adding Blinatumomab to Chemotherapy Improves DFS in Patients with Newly Diagnosed... Qué saber al buscar información sobre el cáncer en línea: perspectiva... Implementation of Molecular Tumour Board Portal Developed Under the Umbrella of... Tebentafusp Shows Promising Clinical Activity with an Acceptable Safety Profile in...
